The benefit of SGLT2 Inhibitors in kidney disease patients with Michael Anger, MD

<p>Originally developed to treat diabetes, SGLT2 inhibitors are potentially groundbreaking in slowing the progression of chronic kidney disease. Recent studies indicate SGLT-2 inhibitors hold promise for slowing CKD progression and for treating heart failure and other cardiovascular conditions.</p> <p>Dr. Michael Anger, Fresenius Medical Care’s chief medical officer for the Renal Therapies Group, joins this episode to discuss how SGLT-2 inhibitors can be used to intervene earlier with kidney disease patients and improve overall patient health.</p>